NuvOx Pharma today announced that Jon S. Saxe has joined its Board of Directors.
Saxe brings to NuvOx many years of experience from the biotechnology, pharmaceutical and venture capital industries. He has served as a director of more than 25 companies and currently is a director of several publicly... - December 28, 2020
NuvOx Pharma, Inc, a clinical stage biopharmaceutical company developing NanO2TM emulsion for oxygen delivery today announced the issuance of US Patent 10,456,468 – Fractionated Radiotherapy and Chemotherapy with an Oxygen Therapeutic. NanO2TM emulsion is designed to increase tumor oxygen levels... - November 03, 2019
Evan Unger, MD, President and CEO of NuvOx Pharma, announced that NuvOx has received a $2M Phase II Small Business Innovation Research (SBIR) grant from the National Cancer Institute to fund the development of a new strategy to detect pancreatic cancer. The grant, 2R44CA203090-02, entitled “Thy-1... - July 14, 2018
NuvOx Pharma, a clinical stage biotechnology company, has received a Phase I SBIR grant for $150,000 from the National Institutes of Health, specifically the National Institute of Neurological Diseases and Stroke (NINDS). This grant will fund development of a novel syringe sonication device that may... - December 30, 2017
The National Heart, Lung, and Blood Institute (NHLBI) has awarded a grant for $317,743 for a study in pigs for NuvOx Pharma's drug, NVX-308, in heart attack. - April 14, 2017
NuvOx Pharma LLC and Jiangsu Nhwa Pharmaceutical Co., Ltd. have signed a licensing agreement for the exclusive development and sales of NVX-408 for China for treating hemorrhagic shock and perioperative blood loss.
NVX-408 is an oxygen therapeutic that is injected intravenously, flows through the lungs... - January 26, 2017
NuvOx Pharma, a Tucson based biotechnology company, has been awarded a grant from the National Cancer Institute for $298,820.00 entitled, “B7-H3-Targeted Contrast Agent for Ultrasonic Imaging of Breast Cancer.” Evan Unger, MD, co-founder of NuvOx, a co-principal investigator of the grant,... - November 03, 2016
NuvOx Pharma, a Tucson based biotechnology company, has been awarded a grant from the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) of the National Institutes of Health for $243,164.00 entitled, “Fibrin Targeted Microbubbles and Ultrasound for Treatment... - August 27, 2016
Evan Unger, MD, President and CEO of NuvOx, announced that the FDA has allowed an investigational new drug application (IND) for NVX-208 (dodecafluoropentane emulsion) to be tested in a Phase Ib trial in stroke patients. The trial will be performed at the University of Arkansas Medical System in Little... - August 22, 2016
Evan Unger, MD, President and CEO of NuvOx Pharma, a Tucson based biotechnology company, announced that the company has been awarded a grant from the National Cancer Institute to develop an ultrasound contrast agent to diagnose pancreatic cancer. The Phase I Small Business Technology Transfer (STTR)... - May 28, 2016
Tucson based pharmaceutical company NuvOx Pharma announced today that it has secured orphan drug designation from the FDA for its investigational drug NVX-508 for vaso-occlusive crisis (VOC) and acute chest syndrome (ACS) in sickle cell disease.
VOC is one of the most severe complications of sickle... - February 14, 2016
The FDA has notified NuvOx Pharma that it may proceed with a clinical trial for its Investigational New Drug (IND), NVX-508 for vaso-occlusive crisis (VOC) and acute chest syndrome (ACS) in sickle cell disease. VOC is one of the most severe complications of sickle cell disease and it typically involves... - February 13, 2016
Tucson based pharmaceutical company NuvOx Pharma announced today that it has secured orphan drug designation from the FDA for its investigational drug NVX-108 for treatment of Glioblastoma. Orphan status provides NuvOx with development and commercial incentives such as tax credits for qualified clinical testing and market exclusivity for 7 years after the marketing approval is granted. - December 07, 2015